Lung Cancer
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results
ESMO Open 2023 June 28 [Link] E B Garon, M Reck, K Nishio, J V Heymach, M Nishio, S Novello, L Paz-Ares, S Popat, S Ponce Aix, H Graham, B D Butts, C Visseren-Grul, K Nakagawa; RELAY study investigators Abstract Background: Ramucirumab plus erlotinib (RAM + ERL) demonstrated superior progression-free survival (PFS) over placebo +…
Read MoreUltrasensitive dose-response for asbestos cancer risk implied by new inflammation-mutation model
Environmental Health 2022 December 21 [Link] Kenneth T Bogen Abstract Alterations in complex cellular phenotype each typically involve multistep activation of an ultrasensitive molecular switch (e.g., to adaptively initiate an apoptosis, inflammasome, Nrf2-ARE anti-oxidant, or heat-shock activation pathway) that triggers expression of a suite of target genes while efficiently limiting false-positive switching from a baseline…
Read MoreRate advancement measurement for lung cancer and pleural mesothelioma in asbestos-exposed workers
Thorax 2022 November 10 [Link] Danila Azzolina, Dario Consonni, Daniela Ferrante, Dario Mirabelli, Stefano Silvestri, Ferdinando Luberto, Alessia Angelini, Francesco Cuccaro, Anna Maria Nannavecchia, Enrico Oddone, Massimo Vicentini, Francesco Barone-Adesi, Tiziana Cena, Lucia Mangone, Francesca Roncaglia, Orietta Sala, Simona Menegozzo, Roberta Pirastu, Sara Tunesi, Elisabetta Chellini, Lucia Miligi, Patrizia Perticaroli, Aldo Pettinari, Vittoria Bressan, Enzo…
Read MoreHypothesis: HEG1 and claudin-4 staining will allow a diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases
Histopathology 2022 August 25 [Link] Andrew Churg, Julia R Naso Abstract Separation of mesothelioma from metastatic carcinoma requires immunohistochemical support, with small batteries of stains recommended as a starting-point, but these numbers commonly expand to 10, 12 or more stains, a process that is not only expensive but frequently generates anomalous or confounding results, leading…
Read MoreLurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma
European Journal of Cancer 2022 July 11 [Link] Daphne W Dumoulin, Luca Cantini, Robin Cornelissen, Madelief Vink, Larissa Klaase, Kick Sloof, Nura Tebayna, Joanne M Mankor, Sara J Baart, Rudi Hendriks, Anne-Marie C Dingemans, Marcella Willemsen, Joachim G J V Aerts Abstract Purpose: Lurbinectedin is a promising new drug being investigated in pre-treated patients with…
Read MoreLung cancer and mesothelioma risks in a prospective cohort of workers with asbestos-related lung or pleural diseases
American Journal of Industrial Medicine 2022 June 1 [Link] Dirk Taeger, Katharina Wichert, Martin Lehnert, Swaantje Casjens, Beate Pesch, Daniel G Weber, Thomas Brüning, Georg Johnen, Thomas Behrens Abstract Background: Asbestos causes mesothelioma and lung cancer. In the European Union, asbestos was banned in 2005, but it is still in use in many other countries.…
Read MoreHeadspace Volatile Organic Compound Profiling of Pleural Mesothelioma and Lung Cancer Cell Lines as Translational Bridge for Breath Research
Frontiers in Oncology 2022 May 6 [Link] Eline Janssens, Zoë Mol, Lore Vandermeersch, Sabrina Lagniau, Karim Y Vermaelen, Jan P van Meerbeeck, Christophe Walgraeve, Elly Marcq, Kevin Lamote Abstract Introduction: Malignant pleural mesothelioma (MPM) is a lethal cancer for which early-stage diagnosis remains a major challenge. Volatile organic compounds (VOCs) in breath proved to be…
Read MoreEffects of inhalable gene transfection as a novel gene therapy for non-small cell lung cancer and malignant pleural mesothelioma
Scientific Reports 2022 May 23 [Link] Misa Ichikawa, Naomi Muramatsu, Wataru Matsunaga, Takahiro Ishikawa, Tomoyuki Okuda, Hirokazu Okamoto, Akinobu Gotoh Abstract Gene therapy using vectors has attracted attention in recent years for the treatment of cancers caused by gene mutations. Besides, new treatments are imperative for lung cancer, including non-small cell lung cancer (NSCLC) and…
Read MoreDiagnostic method for malignant pleural effusion distinguishing malignant mesothelioma from lung cancer using pleural carcinoembryonic antigen and hyaluronic acid levels
Medicine 2022 January 7 [Link] Takeshi Saraya, Kosuke Ohkuma, Masachika Fujiwara, Haruyuki Ishii Abstract Malignant mesothelioma (MM) is difficult to diagnose because of the lack of parenchymal opacities, often revealing minimal or absent pleural thickening. Furthermore, pleural effusion has diverse differential diagnoses, including malignancies, infections, as well as collagen vascular and other benign diseases. In…
Read MoreHighly sensitive quantification of pemetrexed in human plasma using UPLC-MS/MS to support microdosing studies
Biomedical Chromatography 2021 November 5 [Link] Eleonora W J van Ewijk-Beneken Kolmer, Marga J A Teulen, Rene J Boosman, Nikki de Rouw, Jacobus A Burgers, Rob Ter Heine Abstract Pemetrexed is an antifolate drug approved for the treatment of non-small-cell lung cancer and mesothelioma. Assessing pemetrexed pharmacokinetics after administration of a microdose (100 μg) may…
Read More